These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
126 related articles for article (PubMed ID: 36804546)
1. Regulation of human endothelial cell migration by oral contraceptive estrogen receptor ligands. Dama A; Baggio C; Trevisi L; Bolego C; Cignarella A Eur J Pharmacol; 2023 Apr; 945():175591. PubMed ID: 36804546 [TBL] [Abstract][Full Text] [Related]
2. Evaluation of the effect of a new oral contraceptive containing estetrol and drospirenone on hemostasis parameters. Douxfils J; Klipping C; Duijkers I; Kinet V; Mawet M; Maillard C; Jost M; Rosing J; Foidart JM Contraception; 2020 Dec; 102(6):396-402. PubMed ID: 32956694 [TBL] [Abstract][Full Text] [Related]
3. Effects of an oral contraceptive containing estetrol and drospirenone on ovarian function. Duijkers I; Klipping C; Kinet V; Jost M; Bastidas A; Foidart JM Contraception; 2021 Jun; 103(6):386-393. PubMed ID: 33689786 [TBL] [Abstract][Full Text] [Related]
4. Unique effects on hepatic function, lipid metabolism, bone and growth endocrine parameters of estetrol in combined oral contraceptives. Mawet M; Maillard C; Klipping C; Zimmerman Y; Foidart JM; Coelingh Bennink HJ Eur J Contracept Reprod Health Care; 2015; 20(6):463-75. PubMed ID: 26212489 [TBL] [Abstract][Full Text] [Related]
5. Non-genomic mechanisms in the estrogen regulation of glycolytic protein levels in endothelial cells. Boscaro C; Carotti M; Albiero M; Trenti A; Fadini GP; Trevisi L; Sandonà D; Cignarella A; Bolego C FASEB J; 2020 Sep; 34(9):12768-12784. PubMed ID: 32757462 [TBL] [Abstract][Full Text] [Related]
6. The Glycolytic Enzyme PFKFB3 Is Involved in Estrogen-Mediated Angiogenesis via GPER1. Trenti A; Tedesco S; Boscaro C; Ferri N; Cignarella A; Trevisi L; Bolego C J Pharmacol Exp Ther; 2017 Jun; 361(3):398-407. PubMed ID: 28348059 [TBL] [Abstract][Full Text] [Related]
7. Endocrine and metabolic effects of an oral contraceptive containing estetrol and drospirenone. Klipping C; Duijkers I; Mawet M; Maillard C; Bastidas A; Jost M; Foidart JM Contraception; 2021 Apr; 103(4):213-221. PubMed ID: 33428907 [TBL] [Abstract][Full Text] [Related]
8. Regulatory effects of estetrol on the endothelial plasminogen pathway and endothelial cell migration. Montt-Guevara MM; Palla G; Spina S; Bernacchi G; Cecchi E; Campelo AE; Shortrede JE; Canu A; Simoncini T Maturitas; 2017 May; 99():1-9. PubMed ID: 28364860 [TBL] [Abstract][Full Text] [Related]
9. Focal adhesion kinase (FAK) activation by estrogens involves GPER in triple-negative breast cancer cells. Rigiracciolo DC; Santolla MF; Lappano R; Vivacqua A; Cirillo F; Galli GR; Talia M; Muglia L; Pellegrino M; Nohata N; Di Martino MT; Maggiolini M J Exp Clin Cancer Res; 2019 Feb; 38(1):58. PubMed ID: 30728047 [TBL] [Abstract][Full Text] [Related]
10. GPER mediates activation of HIF1α/VEGF signaling by estrogens. De Francesco EM; Pellegrino M; Santolla MF; Lappano R; Ricchio E; Abonante S; Maggiolini M Cancer Res; 2014 Aug; 74(15):4053-64. PubMed ID: 24894716 [TBL] [Abstract][Full Text] [Related]
11. Serum lipid and lipoprotein changes induced by new oral contraceptives containing ethinylestradiol plus levonorgestrel or desogestrel. Gaspard UJ; Buret J; Gillain D; Romus MA; Lambotte R Contraception; 1985 Apr; 31(4):395-408. PubMed ID: 3159546 [TBL] [Abstract][Full Text] [Related]
12. Some estrogenic effects of two oral contraceptives consisting of norgestrel and two different doses of ethynylestradiol. Miller JF; Fotherby K; Bye PG; Elstein M Contraception; 1979 Jul; 20(1):5-10. PubMed ID: 573191 [TBL] [Abstract][Full Text] [Related]
13. Studies on oral contraceptive-induced changes in blood coagulation and fibrinolysis and the estrogen effect on endothelial cells. Quehenberger P; Kapiotis S; Pärtan C; Schneider B; Wenzel R; Gaiger A; Speiser W Ann Hematol; 1993 Jul; 67(1):33-6. PubMed ID: 8392873 [TBL] [Abstract][Full Text] [Related]
14. Selectivity and minimal androgenicity of norgestimate in monophasic and triphasic oral contraceptives. Anderson FD Acta Obstet Gynecol Scand Suppl; 1992; 156():15-21. PubMed ID: 1324552 [TBL] [Abstract][Full Text] [Related]
15. Ovarian function is effectively inhibited by a low-dose triphasic oral contraceptive containing ethinylestradiol and levonorgestrel. Gaspard UJ; Dubois M; Gillain D; Franchimont P; Duvivier J Contraception; 1984 Apr; 29(4):305-18. PubMed ID: 6430638 [TBL] [Abstract][Full Text] [Related]
16. Plasma levels of ethinylestradiol (EE) during cyclic treatment with combined oral contraceptives. Kaufman JM; Thiery M; Vermeulen A Contraception; 1981 Nov; 24(5):589-602. PubMed ID: 7318439 [TBL] [Abstract][Full Text] [Related]